Raymond James Maintains Outperform on Revolve Gr, Lowers Price Target to $62

Raymond James analyst Aaron Kessler maintains Revolve Gr (NYSE:RVLV) with a Outperform and lowers the price target from $73 to $62.

byBenzinga Newsdesk

May 4, 2022

1 minute read

Raymond James analyst Aaron Kessler maintains Revolve Gr (NYSE:RVLV) with a Outperform and lowers the price target from $73 to $62.

Barclays Maintains Underweight on Aramark, Raises Price Target to $36

By Benzinga Newsdesk

Today, 6:17 AM

Barclays analyst Manav Patnaik maintains Aramark (NYSE:ARMK) with a Underweight and raises the price target from $34 to $36.

ARMK

Inozyme Pharma Q3 EPS $(0.60) Up From $(1.55) YoY

By Benzinga Newsdesk

Today, 6:17 AM

Inozyme Pharma (NASDAQ:INZY) reported quarterly losses of $(0.60) per share. This is a 61.29 percent increase over losses of $(1.55) per share from the same period last year.

INZY

Truist Securities Maintains Hold on Atlassian Corporation, Raises Price Target to $250

By Benzinga Newsdesk

Today, 6:17 AM

Truist Securities analyst Joel Fishbein maintains Atlassian Corporation (NASDAQ:TEAM) with a Hold and raises the price target from $220 to $250.

TEAM

News

Zentalis Pharmaceuticals Announces Updates Across Its Pipeline Including Promising New Interim Clinical Data On ZN-c3 And ZN-c5 And Two Potentially Registrational Trials For ZN-c3, With The First Trial Already Initiated

By Benzinga Newsdesk

Today, 6:17 AM

Reports additional ZN-c3 Phase 1 interim monotherapy data, demonstrating increased tumor reduction and durability in the exceptional responder population, as well as newly confirmed responses and an additional

ZNTL

Raymond James Maintains Outperform on Revolve Gr, Lowers Price Target to $62

Related Posts

Barclays Maintains Underweight on Aramark, Raises Price Target to $36

Inozyme Pharma Q3 EPS $(0.60) Up From $(1.55) YoY

Truist Securities Maintains Hold on Atlassian Corporation, Raises Price Target to $250

Zentalis Pharmaceuticals Announces Updates Across Its Pipeline Including Promising New Interim Clinical Data On ZN-c3 And ZN-c5 And Two Potentially Registrational Trials For ZN-c3, With The First Trial Already Initiated